Alnylam Pharmaceuticals' Gains from Investment Securities rose 98.14% to $3.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $17.0 million, marking a year-over-year increase of 50.30%. This contributed to the annual value of $14.4 million for FY2024, which is 138.50% up from last year.
Per Alnylam Pharmaceuticals' latest filing, its Gains from Investment Securities stood at $3.8 million for Q3 2025, which was up 398.06% from -$1.3 million recorded in Q2 2025.
Over the past 5 years, Alnylam Pharmaceuticals' Gains from Investment Securities peaked at $9.8 million during Q1 2025, and registered a low of -$1.3 million during Q2 2025.
For the 3-year period, Alnylam Pharmaceuticals' Gains from Investment Securities averaged around $3.6 million, with its median value being $3.8 million (2025).
In the last 5 years, Alnylam Pharmaceuticals' Gains from Investment Securities surged by 3,130.30% in 2022 and then tumbled by 122.20% in 2025.
Alnylam Pharmaceuticals' Gains from Investment Securities (Quarterly) stood at -$165,000 in 2021, then spiked by 3,130.30% to -$381,000 in 2022, then skyrocketed by 515.49% to $1.6 million in 2023, then soared by 192.36% to $4.6 million in 2024, then spiked by 98.14% to $3.8 million in 2025.
Its Gains from Investment Securities was $3.8 million in Q3 2025, compared to -$1.3 million in Q2 2025 and $9.8 million in Q1 2025.

Peer Comparison

Historic Data

Download Data 🔒

Date	Value